Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 and Cathelicidin in COPD and Smokers
NCT02464059Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Nov 2015
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vitamin d in chronic obstructive pulmonary disease (COPD), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Change From Baseline in Lung Cathelicidin Level at 8 weeks. Started Nov 2015; status: completed.
02
Drugs
vitamin d
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02464059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464059.